ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

Conditions

• Acute Hepatic Porphyria

Eligibility Criteria

Sex

ALL

Age

12 Years - N/A

Healthy Volunteers

Not accepted

Study Details

This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.

Key Dates

Start date

Apr 26, 2021

Status verified

Apr 2026

Primary completion

Apr 1, 2027

Completion

Apr 1, 2027

Study Design

Enrollment

150 participants (estimated)

Arms

• Arm: Patients with AHP
  Patients with a diagnosis of AHP will be eligible for the study and will be managed and treated per routine clinical practice.

Primary Outcome Measure

Incidence of Selected Events of Interest in AHP Patients [ Time Frame: Up to 6 years ]

Central Contacts

• Alnylam Clinical Trial Information Line
  1-877-ALNYLAM
  [email protected]
• Alnylam Clinical Trial Information Line
  1-877-256-9526
  [email protected]

Locations (13)

Find similar trials in Birmingham, AL